Join former physician, now CEO of immuno-diagnostics company, Adam M Hill as he speaks with leading experts and peers from across the healthcare and life science industry to discuss the opportunities and challenges they’re facing and what drives them to work towards delivering scalable improvements in health outcomes.
Dr Annalisa Jenkins
On International Women's Day, Adam talks with Dr Annalisa Jenkins, one of the industry’s most accomplished leaders.
Annalisa’s inspirational career spans over 25 years in the global biopharma industry – she started her career at St Barts, in London, where she trained as a cardiologist, before joining the British Royal Navy as a medical officer during the Gulf Conflict, achieving the rank of surgeon lieutenant commander during her time there.
Annalisa spent almost two decades producing a pipeline of innovation at Bristol Myers Squibb and Merck Serono – she has built and led scientific, regulatory and medical affairs teams to advance programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally.
More recently, Annalisa, has focussed her experience on building and financing biotech companies, pursuing cures for the most challenging rare diseases and working to address important medical issues globally. She served as President and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx in 2017.
Annalisa is a committee member of the Science Board to the U.S. Food & Drug Administration, board member at Faster Cures, a centre of The Milken Institute and Chair of The Court at The London School of Hygiene and Tropical Medicine.
She also sits on the board of many growing companies and is a fierce champion for diversity and inclusion, particularly for women in science.
Dr James Jett
Adam talks to Dr James Jett, a leader in the field of pulmonology whose career spans more than four decades. Jim was Professor of Medicine at the Mayo Clinic for almost 30 years before joining the National Jewish in Denver, Colorado. Jim was Editor in Chief of the Journal of Thoracic Oncology for almost 10 years and additionally has served in journal review and editorial activities for numerous medical publications, including the American Journal of Respiratory and Critical Care Medicine, Cancer, Chest and The New England Journal of Medicine. Jim now works with Biodesix, in Colorado as their Chief Medical Officer where he continues to support work in lung cancer.
Jim talks about the advances that he has seen in lung cancer over his career and what he is most optimistic about in lung cancer diagnosis and treatment. He also talks about what impact COVID-19 has had on the healthcare system in the US, what long term impact it might on the early detection of cancer and what silver linings he has observed in the pandemic cloud.
Dr Parag Mallick
Adam talks to Dr Parag Mallick from Stanford University where he is a Professor. Having originally trained as an engineer biochemist, Parag's research is diverse and spans computational and experimental systems biology, cancer biology, and nanotechnology.
Parag talks about the diverse applications of proteomics and the value of bringing together different perspectives and disciplines to tackle challenging problems like biomarker analysis and personalised medicine. He also talks about the importance of and future opportunity for bioinformatics and shares his thoughts on the broader recognition of early detection that started to gain momentum in immuno-oncology but has now expanded to other treatment modalities.
Professor Ola Winqvist
Adam talks to Ola Winqvist, Professor of Cellular Immunotherapy at the Karolinska Institute and Chief Physician of Clinical Immunology at the Karolinska University Hospital.
Ola gives Adam a primer on the immune system, how it responds to disease and infection, and particularly, the role of autoantibodies as biomarkers or targets for some therapies. Ola also talks about the changes he has seen in in the field of immunology over the last thirty years and he shares his thoughts on how Sweden has managed the pandemic.
Professor Chris Molloy
Adam talks to Professor Chris Molloy, CEO of the UK's Medicines Discovery Catapult, the National Research Technology Facility supporting the sector by industrialising and driving the adoption of new approaches to discovering medicines.
Most recently, Chris has been responsible for establishing and running the Lighthouse Labs, the biggest diagnostic lab in British history. Developed in partnership with AstraZeneca and GSK, these labs provide diagnostics infrastructure, which have the capability to test tens of thousands of patient samples each day for Coronavirus.
Chris talks about the herculean task he and his team had in setting up the LightHouse Labs, what he is most proud of and with the lab infrastructure now in place, what are the opportunities to test, trace, and better stratify patients into various forms of therapies in the United Kingdom.
Dr Richard Roope
Adam talks to Dr Richard Roope, a General Practitioner with a special interest in cancer management and Senior Clinical Advisor (for Prevention and Early Diagnosis) at Cancer Research UK. As we find ourselves in the middle of a pandemic, which has put extreme pressure on cancer services globally, Richard discusses our biggest challenge when it comes to cancer management. He also talks about why it is we have seen less referrals for all cancers and lung cancer in particular, and how we can reach out to the missing patients.